NCT05972473View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

April 30, 2027

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Aflibercept Ophthalmic

2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).

BIOLOGICAL

IBI302

8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY